Traders should await the actual earnings release and management commentary on March 19 for any material updates on cash runway, trial progress, or funding plans. Absence of data makes this pre-announcement low impact.
Price Chart
Executive Summary
Relmada Therapeutics announced plans to host a conference call on March 19, 2026, to discuss its Q4 and full-year 2025 financial results. The press release contains no actual financial data, guidance, or material business updates, serving only as a notification of the upcoming earnings event.
Key Facts
- Relmada Therapeutics will host a conference call on March 19, 2026, at 4:30 PM ET to discuss Q4 and full-year 2025 financial results.
- No financial results, guidance, or material operational updates were disclosed in the press release.
- The company remains in clinical-stage development with lead candidates NDV-01 and sepranolone in mid-stage trials.
Financial Impact
None disclosed — no financial figures released
Risk Factors
- Lack of disclosed financials increases information asymmetry ahead of the call.
- Clinical-stage biotech with no near-term revenue — stock remains highly speculative.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3254447 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 11, 2026 21d ago | Insider Cluster | $4.52 $4.12 | ▼ −8.85% | ▼ −8.63% | $3.60 (−20.35%) |
May 13, 2026 20w ago | S-3ASR | $7.42 $7.21 | ▲ +2.83% | ▲ +2.11% | $3.60 (+51.48%) |
May 12, 2026 20w ago | 8-K | $7.49 $7.03 | ▼ −6.14% | ▼ −4.98% | $3.60 (−51.94%) |
Apr 17, 2026 23w ago | DEFA14A | $7.37 $7.03 | ▼ −4.61% | ▼ −5.53% | $3.60 (−51.15%) |
Apr 3, 2026 25w ago | S-3 | $6.90 $7.38 | ▲ +6.96% | ▲ +2.82% | $3.60 (−47.83%) |
Mar 19, 2026 28w ago | Press Release | $6.07 $6.43 | ▲ +5.93% | ▲ +8.08% | $3.60 (−40.69%) |
Mar 12, 2026 29w ago | Press Release | $6.15 $6.25 | ▲ +1.63% | ▲ +2.60% | $3.60 (−41.46%) |
Mar 9, 2026 29w ago | Press Release | $7.17 $6.18 | ▼ −13.81% | ▼ −12.45% | $3.60 (−49.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access